Possible distribution or partnerships/ takeovers (Hypothetical only), page-96

A little more research for my own curiosity
Baxter Ventures -supporting healthcare innovation..
"Investment PhilosophyBaxter Ventures invests in companies with innovative technologies, products, and therapies that accelerate growth and advance patient care. Each investment opportunity undergoes a rigorous evaluation process to determine if it has the potential to address unmet clinical needs and offer sustainable long-term growth.Areas of Interest Include:In-Hospital Solutions and TherapeuticsCritical CareSurgical CareMedical DevicesMonitoring and Diagnostic ToolsMedication Delivery and ManagementPharmacy Technology ToolsRenal TherapiesHealthcare Information Technology"

 A possibility given they advertise joint venture or investments in innovation with "Diagnostic Tools" BD1s has three to commercialise. 
Who else

Top key contenders I could find Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.). 

 A quick count of acquisition, investments and joint ventures  was interesting reading. Each of these eight companies could/would be watching BD1 and hundreds of others trying to crack the market for new blood tests for breast, ovarian and lung cancers. Given my poor and limited research there are possibly a lot more than these eight.

I wonder if some are already on the share register? It would be interesting reading but as it is likely the names of subsidiary companies would be used to mask investments by Companies as big as these listed. 

Never forgetting for a moment that Thermo Fisher is developing the commercial tests. That's not a freebie. A list of what they do here in Australia is extensive  . I have not noted how much we have paid them Next Qtrs r&d is $200,000 only. My thoughts is the main contender is already well known to us. Thermo Fisher is in the box seat with assay test development "in readiness to commence clinical studies for both BARD1-Breast and BARD1-Ovarian to evaluate clinical performance in 2H19"

The nice bit is it is Thermo Fisher is not the only contender and anyone else wanting in to our party will need a large chunk of shares to get a seat at the table if the door is currently closed to them. A measly market cap of 21 million is not even a sneeze to any of the listed contenders. 

This is pure conjecture on my part of course.